{"schema_version":"secwatch.filing_event.v1","accession":"0001490978-22-000011","form_type":"8-K","ticker":"SDGR","cik":"0001490978","company_name":"Schrodinger, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.827885+00:00","generated_at":"2026-06-22T08:49:11.981156+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Schrodinger Q3 rev $37M (+24% YoY); Lilly collab up to $425M; FY22 guide narrowed","bullets":["Q3 total revenue $37.0M (+24% YoY); drug discovery $12.3M (+121%); software $24.7M (+2%)","Net loss $39.9M vs $35.0M; cash $479M vs $513M at June 30, 2022","Entered collaboration with Lilly; up to $425M in milestones plus tiered royalties","Phase 1 trial of MALT1 inhibitor SGR-1505 open for patient enrollment","FY22 total revenue guide narrowed to $167-175M; software rev lowered to $122-127M; drug discovery raised to $45-48M"],"urls":{"canonical":"https://secwatch.observer/filing/0001490978-22-000011","json":"https://secwatch.observer/filing/0001490978-22-000011.json","markdown":"https://secwatch.observer/filing/0001490978-22-000011.md","text":"https://secwatch.observer/filing/0001490978-22-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1490978/000149097822000011/0001490978-22-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1490978/000149097822000011/sdgr-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:49:11.981156+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"648b3ee71bfb722b541cf9934f02ff3e65d57502","claim":"Schrodinger, Inc. updated its the fiscal year ending December 31, 2022 guidance (reaffirmed).","evidence_excerpt":"Total revenue is now expected to range from $167 million to $175 million, compared to the prior expectation of $161 million to $181 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097822000011/0001490978-22-000011-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ending December 31, 2022"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"98f3b42b24ae2ae78c665277f1fb519502d5fc82","claim":"Schrodinger, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 3, 2022, Schrödinger, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097822000011/0001490978-22-000011-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}